Nektar Therapeutics (NKTR) Sank To A 6-Month Low On Study Results

Nektar Therapeutics (NKTR) presented disappointing results from its Phase 1/2 study of the combination of Bristol-Myers Squibb's (BMY) Opdivo with Nektar's NKTR-214 Monday morning.

from RTT - Before the Bell https://ift.tt/2HiTM7X
via IFTTT